Form 4: Cytek Biosciences CLO Executes RSU Vesting Transaction

Chief Legal Officer Valerie Barnett reported the vesting and partial withholding of restricted stock units for tax obligations.

Summary

• Valerie Barnett, Chief Legal Officer of Cytek Biosciences, Inc., exercised the vesting of 24,295 restricted stock units (RSUs) on May 18, 2026.
• A total of 8,719 shares were withheld by the company to satisfy mandatory tax withholding requirements at a price of $3.55 per share.
• Following these transactions, the reporting person holds a total of 150,012 shares of common stock.
• The transactions represent standard equity compensation vesting and do not indicate a discretionary sale of shares by the executive.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation that carries no signal regarding company performance or strategic direction.

Positives

• The transaction reflects the ongoing vesting of equity compensation, aligning the executive's interests with long-term shareholder value.
• The executive maintains a significant beneficial ownership position of 150,012 shares.

Negatives

• The withholding of 8,719 shares for tax purposes results in a minor reduction of potential net share ownership for the executive.

Risks

• The company's share price performance directly impacts the value of unvested RSU awards held by management.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of insider equity transactions.

Industry Context

StockSavvy.ai notes that routine RSU vesting and tax-related share withholding are standard corporate governance practices in the biotechnology sector, reflecting typical executive compensation structures rather than shifts in corporate strategy or market outlook.

Comparison to Industry Standards

• The transaction structure is consistent with standard equity compensation practices for C-suite executives in publicly traded life sciences companies.
• The use of 'sell-to-cover' or share withholding for tax obligations is a common industry practice to manage personal tax liabilities associated with equity vesting.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a routine equity compensation event.

Next Steps

• Future vesting of remaining RSU awards according to the established 4-year schedule.

Key Dates

Keywords

Cytek Biosciences, CTKB, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Biotechnology